The worst mistake Moderna investors can make right now

The COVID-19 vaccine could be the first of a long list of successes.

| More on:
asx share price growth represented by hand holding hourglass surrounded by dollar signs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

In late 2018, Moderna Inc (NASDAQ: MRNA) went public in the largest biotech initial public offering (IPO) in history. Its value barely moved until mid-February 2020, when COVID-19 cases in the U.S. started showing up in multiple states. Now that its coronavirus vaccine has received Emergency Use Authorization, some investors might think there is limited upside left in the stock. That thinking might lead shareholders of Moderna to do the worst thing they could do right now.

Warp speed and beyond

Working with the National Institute of Allergy and Infectious Diseases, the company delivered a vaccine just 42 days after the genome sequence of the novel coronavirus was made public. Since then, the U.S. government has provided $4.1 billion to the company to get the drug to market, and will purchase 200 million doses of the vaccine with an option to buy 300 million more. Management's base case is for 600 million of the doses to be available by the end of 2021.

Much has been made about using mRNA for its vaccine, but patented fat molecules that deliver the genetic instructions to the cell are also part of the secret sauce. Without these, a strong response from the immune system would destroy both carrier and cargo. On a December investor conference call, CEO Stephane Bancel referenced the 20 products in the company's pipeline using this approach, asserting capital had been a limiting factor in the past. Now, with $4 billion of cash on the balance sheet, he expects more successful launches such as the potential for $2 billion to $5 billion in sales from the company's cytomegalovirus vaccine, which is currently in a phase 2 trial. 

Selling the stock now that one drug is authorized may lock in a profit, but Moderna's most valuable asset could be its platform for drug development. If so, it will take years to play out. Shareholders who sell now could be giving up on the company just as it's starting to revolutionize how diseases are treated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Beautiful holiday photo showing two deck chairs close-up with people sitting in them enjoying the bright blue ocean and island view while sipping champagne and enjoying the good life thanks to Pilbara Minerals share price gains in recent times
International Stock News

Billionaire Ray Dalio sold Nvidia stock. Should you follow?

Billionaire Ray Dalio and his firm made an interesting move during the third quarter. They sold Nvidia stock. Should you…

Read more »

A man looking at his laptop and thinking.
International Stock News

Why Alphabet stock was sliding today

Let's take a look.

Read more »

A man looking at his laptop and thinking.
International Stock News

Nvidia's stock was down despite its amazing earnings. Here's what history says is coming next

Although it might seem to defy logic, it's not an uncommon phenomenon.

Read more »

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Nvidia share price slips despite 94% revenue growth

Q3 earnings beat expectations, but what about guidance?

Read more »

high, climbing, record high
International Stock News

Could the S&P 500 Index hit 6,500 by the end of 2025?

Could the index climb higher?

Read more »

a small child holds his chin with his head on the side in a serious thinking pose against a background of graphic question marks and a yellow lightbulb.
International Stock News

Is it too late to buy Nvidia shares?

Is Nvidia stock a buy ahead of its third-quarter earnings report tomorrow?

Read more »

a group of people stand examining a large glowing cystral ball held in the hands of one of the group members while the others regard it with various expressions of wonder, curiousity and scepticism.
International Stock News

Here's what to expect from Nvidia on November 20

Can Nvidia score another win?

Read more »

Two people lazing in deck chairs on a beautiful sandy beach through their hands up in the air.
International Stock News

2 no-brainer Warren Buffett stocks to buy right now

While replicating Buffett's success isn't possible, there are a handful of his investments that are no-brainer buys.

Read more »